Vitamin K2 as MK-7 is now known as an essential nutrient for all life’s stages because:
- NattoPharma has sponsored all the research confirming safety and efficacy, providing MenaQ7 as the source material for 19+ published clinical studies.
- NattoPharma actively engages media to educate about clinical discoveries, creating demand.
These ongoing efforts open new avenues for manufacturers, creating true potential for products. And with 3 points of differentiation between MenaQ7 and all other Vitamin K2s, your products can deliver on their promise to improve health … provided they feature MenaQ7.
The best clinically validated vitamin K2
NattoPharma is an undisputed leader in clinical understanding and science. Our ongoing investment in groundbreaking research allows us to identify novel health benefits and open up new market opportunities for our partners.
More than 19 published clinical studies have demonstrated the high bioavailability and proof of efficacy for NattoPharma’s all-trans MK-7 products:
MenaQ7 in healthy populations
- van Summeren et al. British Journal of Nutrition. 2009
- Theuwissen et al. British Journal of Nutrition. 2012
MenaQ7 for bone health
- van Summeren et al. British Journal of Nutrition. 2009
- Knapen et al. Osteoporosis International. 2013
MenaQ7 for kidney health
- Westenfeld et al. American Journal of Kidney Disease. 2012
- Calwuè et al. Nephrology Dialysis Transplant. 2014
- Kurnatowska et al. Polish Archives of Internal Medicine. 2015
- Aoun et al. BMC Nephrology. 2017
- Mansour et al. Journal of the American Society of Hypertension. 2017
MenaQ7 for optimal bioavailability
- Schurgers et al. Blood. 2007
- Sato et al. Nutrition Journal. 2012
MenaQ7 for cardiovascular health
- Dalmeijer et al. Atherosclerosis. 2012
- Chatrou et al. Blood Review. 2012
- Theuwissen et al. Advanced Nutrition. 2012
- Knapen et al. Thrombosis and Haemostasis. 2015
- Knapen et al. Journal of Nutritional Science. 2015
- Knapen et al. European Journal of Clinical Nutrition. 2016
- Kurnatowska et al. Polish Archives of Internal Medicine. 2015
- Aoun et al. BMC Nephrology. 2017
- Mansour et al. Journal of the American Society of Hypertension. 2017
NattoPharma has more trials currently underway. This dedication has earned the attention of European research groups awarding NattoPharma millions of Euros in grants.
The ONLY comprehensive vitamin K2 portfolio
Since MenaQ7 was first introduced, novel technologies have been pioneered to expand the product portfolio. Today, the MenaQ7 product range caters to a growing global demand of high-purity, stable, and well-researched Vitamin K2 as MK-7, and is offered as:
MenaQ7 Natural MK-7: Naturally derived Vitamin K2 as MK-7 uses a fermentation medium with chickpea protein and Bacillus licheniformis. The result is a MenaQ7 variety free from all known allergens including soy. A proprietary multi-step process of purification produces a product that is more than 96% pure, all-trans MK-7. In addition, MenaQ7 Natural is Non-GMO certified, suitable for Vegans, Gluten free and Free of cis-isomers.
MenaQ7 Natto MK-7: NattoPharma re-launched its natural soy based MenaQ7 Vitamin K2 product offering to ensure the increasingly diversified market is supplied with an ingredient matching their K2 needs. MenaQ7 Natto is manufactured using a soybean protein substrate for Bacillus subtilis fermentation. The MK-7 is extracted using the proprietary multi-step process of purification and condensation, leading to an unparalleled 96% active all-trans soy fermented ingredient that is further blended in oils or powders.
MenaQ7 PharmaPure MK-7: An award-winning, nature-identical synthetic Vitamin K2, MenaQ7 PharmPure is the only all-trans synthetic available that is free of cis-isomers. Bioequivalent to the soy and natural chickpea preparations, the MenaQ7 PharmaPure product line provides the same technical and clinical benefits, including being free from all known allergens, but at a sensitive price point.
A fit for any delivery application thanks to solution-driven technologies
Each MenaQ7 variety is offered in multiple dilutions and solubilities. The NattoPharma R&D Solutions team is ready to help bring your product vision to life, pairing the right variety of MenaQ7 in the correct form, compared against the Advance Delivery Platform.
In addition, NattoPharma’s research shows that moisture and mineral salts are critical variables for Vitamin K2 degradation, driving the need for a protective technology.
The Answer: CryoCap, a NattoPharma Advance Delivery Platform technology developed specifically for dry delivery applications pairing MenaQ7 Vitamin K2 as MK-7 with interactive compounds, such as alkaline minerals or oxidative ingredients.
NattoPharma, the leader in Vitamin K2 R&D, has conducted rigorous “stress- testing” on our CryoCap technology, confirming our superiority to our competitors’ offerings. Our team works closely with our partners to develop the right solution for their product goals.
Contact NattoPharma today to learn more about CryoCap and incorporating our technology in your formulation to ensure the most robust delivery of MenaQ7 Vitamin K2 as MK-7.
